Business Wire

Unifrax Introduces FlexCat™, a New Custom High-Performance Specialty Catalyst Material

Share

Unifrax, the leading manufacturer of high-performance specialty materials, today introduced FlexCat™ by Unifrax, a new high-surface area flexible media designed to provide enhanced catalyst effectiveness with increased yield using fewer raw materials. For use in fuel cells, specialty gas production, chemical processing, air purification and other applications, FlexCat offers catalyzers and industrial partners better performance, considerable cost savings, and improved safety for employees.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210421005357/en/

A game-changing solution for specialty catalyst markets

With many industries currently relying on alumina pellets to drive catalytic reactions, specialty chemical companies often grapple with stalled reactions because of clogged materials, large upfront investments and significant space requirements. They are also forced to contend with environmentally harmful emissions. To address these issues, Unifrax has designed a fibrous catalyst support solution that is 15 times lighter on average than the industry standard, while using significantly less precious metal catalysts and rare earth metals to drive an increase in yield while improving purity. This allows for increased output using existing equipment and enables a smaller reactor footprint for future designs. FlexCat can be incorporated into existing plant emission control systems to drive lower carbon footprints and allowing customers to meet tougher Environmental Protection Agency (EPA) standards.

“FlexCat is a truly revolutionary offering as a very lightweight, customized product form that is extremely durable in the harsh conditions typically encountered in many reactors,” said Chad Cannan, senior vice president of research and development, Unifrax. “FlexCat provides our industry partners with the potential to save millions of dollars across their operations in material costs, capital investments and improved quality from existing equipment. From cleaner emissions to meeting tougher EPA standards to increased purity, flow rates, and conversion speeds, the introduction of FlexCat is a true environmental, social, and governance (ESG) game changer for the industry.”

FlexCat is also poised to impact the hydrogen economy. As the demand for hydrogen increases, FlexCat supports the growth of hydrogen production through better selectivity and increased yield using significantly less catalyst material. FlexCat technology drives greater adoption by utilizing smaller and more efficient units that span from fuel cells to consumer devices.

Fiber-based technology that delivers

Leveraging the effective surface area of Unifrax’s unique fibrous material, FlexCat offers enhanced outputs by providing a more tortuous path for improved catalysis inside a reactor. FlexCat eliminates the need for any prewash or zeolite-coating process before applying catalyst metals. Testing to date has shown:

  • Ability to use up to 80 percent less metal, including platinum group metals (PGMs), while obtaining the same conversion yield
  • Extreme durability to nearly 1,850°F (~1,000°C) with more consistent product purity
  • Enhanced conversion and selectivity of catalytic reactions, even after aging, allowing industrial plants better output with existing equipment
  • Strong adhesion of PGMs and almost no loss of catalyst, even after thermal aging

FlexCat’s lightweight fiber mat structure allows for safer installation and removal, and limits hazardous waste, important benefits for Unifrax’s client’s workforce and the safety of the environment.

FlexCat and Unifrax’s deep technology portfolio

FlexCat is Unifrax’s first step into industrial catalysis, building on the company’s deep history of fiber-based technology and manufacturing. Unifrax has a track record of 75+ years developing and supplying engineered inorganic materials on a large scale to advanced industries worldwide, including electric vehicles, aerospace and chemical processing.

“Unifrax continues to pursue its mission to provide greener, cleaner, and safer solutions for our customers and partners. FlexCat is a revolutionary step forward for industrial catalysis that delivers on those three pillars,” commented John Dandolph, president and CEO, Unifrax. “Unifrax has worked closely with petrochemical and renewable fuels partners throughout our company’s history. As these industries look for new and innovative technologies to deliver cost-savings and efficiencies that current products can’t offer today, products like FlexCat, along with our new vehicle emissions technology Eco-lytic™, deliver unique, game-changing solutions to catalysis industries overall. These products will have a transformational impact on safety, cost, and the environment in hundreds of industrial and chemical processes.”

Customizable for individual partners, processes and specific reactions, FlexCat can be manufactured at scale today. Unifrax will be available at Hydrogen 2021 Digital Conference & Exhibition to discuss in more with interested parties. For more information on the event visit this link.

Learn more about FlexCat at www.unifrax.com/landing-page/flexcat/.

About Unifrax

Unifrax develops and manufactures high-performance specialty materials used in advanced applications, including high-temperature industrial insulation, electric vehicles, energy storage, filtration and fire protection, among many others. Unifrax products are designed with the ultimate goal of saving energy, reducing pollution and improving safety for people, buildings and equipment by delivering on our commitment to our customers of greener, cleaner, safer solutions for their application challenges. Unifrax has 37 manufacturing facilities operating in 12 countries and employs 2,700+ employees globally. More information is available at www.unifrax.com. For updates, follow us on Twitter, LinkedIn, and Facebook.

About Clearlake

Founded in 2006, Clearlake Capital Group, L.P. is an investment firm operating integrated businesses across private equity, credit and other related strategies. With a sector-focused approach, the firm seeks to partner with experienced management teams by providing patient, long-term capital to dynamic businesses that can benefit from Clearlake’s operational improvement approach, O.P.S.® The firm’s core target sectors are industrials, technology and consumer. Clearlake currently has approximately $35 billion of assets under management and its senior investment principals have led or co-led over 300 investments. The firm has offices in Santa Monica and Dallas. More information is available at www.clearlake.com and on Twitter @ClearlakeCap.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Unifrax:
Deborah L. Myers
Global Marketing Communication Director
dmyers@unifrax.com
716.812.4802

For Clearlake:
Jennifer Hurson
jhurson@lambert.com
845.507.0571

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye